Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2021 17:00 ET | Source: BIOPHYTIS SA

Biophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Reserved for NEGMA and the Performance of the Judgments of March 16, 2021 and July 16, 2021

PARIS and CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company...
August 02, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia

Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the 400-meter walk test (400MWT), the primary endpoint of the studySarconeos (BIO101) showed a very...
July 19, 2021 17:00 ET | Source: BIOPHYTIS SA

Judgment Rendered on July 16, 2021 in the Proceedings Between Biophytis and Negma Group Ltd by the Execution Judge From the Paris Court of Justice

PARIS and CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company...
July 12, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

PARIS and CAMBRIDGE, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company...
July 08, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis Reinforces Leadership Teams with Three Senior Appointments

Claude Allary to be member of Board of Directors Benoit Canolle is appointed Chief Business OfficerJean Mariani, Chairman of Biophytis Scientific Committee to take over the Chief Medical Officer role ...
June 30, 2021 17:00 ET | Source: BIOPHYTIS SA

Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021

PARIS and CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”),a clinical-stage biotechnology company...
June 30, 2021 17:00 ET | Source: BIOPHYTIS SA

Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study

The Company signed contracts for the manufacturing of registration batches in view of the potential application for Emergency Use Authorization to FDA and/or Conditional Marketing Authorization to...
June 18, 2021 20:00 ET | Source: BIOPHYTIS SA

Biophytis announces new convertible bond financing for up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million

PARIS and Cambridge, Mass., June 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company...
May 12, 2021 02:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis

This 2nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy dataThe Company is to report the recommendation from the DMC based on its...
May 11, 2021 02:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS - Results of the Combined General Meeting on May 10, 2021

PARIS, France and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “company”), a clinical-stage biotechnology...